Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > When was the CRL received by THTX

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on Jan 24, 2024 8:36am

92 Views

Post# 35842501

RE:RE:When was the CRL received by THTX

What I don't understand FDA notified the company they need more time to review the application and only a day later issue the CRL? If not what was the reason to delay the news by one day? What was the reason for yesterday's PR? None of this make sense. So freaking frustrating.

palinc2000 wrote:
It seems obvious that the CRL was received by THTX yesterday....Why did THTX decide to wait till today to inform the market.... One two punch!!!
Buffoons!!!

palinc2000 wrote: ????